Kisplyx® (lenvatinib) in Combination with everolimus Receives Positive CHMP Opinion in Advanced Renal Cell Carcinoma (y

1. European Medicines Agency. Summary of Opinion (post authorisation) Lenvatinib, July 2016.

2. Motzer R, et al. Randomized phase 2 three-arm trial of lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma. The Lancet Oncology 2015;16:1473-82. Available athttp://www.thelancet.com/journals/lanonc/article/PIIS1470-20.... Last accessed: June 2016

3. Matsui J, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 2008;122:664-671

4 Hutson T, et al. Subgroup analyses from the phase 2 trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in metastatic renal cell carcinoma (mRCC). American Society for Clinical Oncology annual meeting 2016; Poster # 175

5. Ljungberg et al. Guidelines on Renal Cell Carcinoma. Available at: http://uroweb.org/wp-content/uploads/10-Renal-Cell-Carcinoma.... Accessed: June 2016

6. Adachi Y, et al. Lenvatinib in Combination with Everolimus Demonstrated Enhanced Antiangiogenesis and Antitumor Activity in Human RCC Xenograft Models. AACR 2016; #3264

7. Okamoto K, et al. Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization. ACS Med. Chem. Lett 2015;6:89-94

8. SPC Afinitor. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_...  Accessed: June 2016

9. National Cancer Institute at the National Institute of Health. Available at:http://www.cancer.gov/types/kidney/patient/kidney-treatment-...  

10. National Cancer Institute at the National Institute of Health. Available at: http://www.cancer.gov/types/kidneyLast accessed: June 2016

 
Date of preparation: July 2016 
Job code: Lenvatinib-UK0068

CONTACT: Media Enquiries - Eisai: Cressida Robson / Ben Speller,+44(0)7908 314 155 / +44(0)7947 231 513, Cressida_Robson@eisai.net,Ben_Speller@eisai.net | Tonic Life Communications: Alex Davies/CallumHaire, +44(0)7716 324 722 / +44(0)7867 429 637, Alex.Davies@toniclc.com,Callum.Haire@toniclc.com